Stocktoria
Hyperfine, Inc. HYPR
Nasdaq · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2021-01-27
Hyperfine, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | $12.9M | $11.0M | $6.8M | $1.5M | $294,000 |
| Gross profit | $6.8M | $5.9M | $4.8M | $907,000 | -$1.2M | -$477,000 |
| R&D expense | $17.5M | $22.5M | $22.5M | $28.2M | $25.8M | $14.6M |
| Operating income | -$37.1M | -$43.2M | -$48.1M | -$73.9M | -$64.9M | -$23.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$35.6M | -$40.7M | -$44.2M | -$44.2M | -$64.9M | -$23.4M |
| EPS (diluted) | $-0.43 | $-0.56 | $-0.62 | $-1.04 | $-17.57 | — |
| Operating cash flow | -$27.9M | -$38.8M | -$41.8M | -$72.3M | -$47.2M | -$21.5M |
| Free cash flow | -$29.1M | -$39.1M | -$42.6M | -$72.9M | -$49.9M | -$23.1M |
| Cash & equivalents | $35.1M | $37.6M | $75.2M | $117.5M | $188.5M | $62.7M |
| Inventory | $7.1M | $5.8M | $6.6M | $4.6M | $4.3M | $1.7M |
| Total assets | $55.3M | $58.9M | $94.2M | $134.1M | $202.5M | $71.5M |
| Total liabilities | $14.3M | $9.9M | $9.8M | $10.3M | $16.2M | $4.3M |
| Shareholders' equity | $41.0M | $49.0M | $84.4M | $123.7M | $186.2M | -$61.1M |
Growth · year-over-year · Revenue CAGR 115.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +5.2% | +16.8% | +61.9% | +355.5% | +408.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.